- Granules India’s revenue CAGR expected at 15% for finished dosages over FY25-28E
- Q2 FY26 sales met estimates; EBITDA surpassed due to better gross margin
- FY27 anticipated as a growth year post-remediation and new Gagillapur approvals
With current production coming back on stream from Q4 FY26, ramp-up in new launches in the US and other geographies, coupled with improved volumes, the brokerage expects Granules India's revenue CAGR of 15% for the finished dosages over FY25-28E.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Granules India Ltd.'s Q2 FY26 sales were in line with estimates. Ebitda was above estimates, due to better-than-expected gross margin.
Management believes FY27 will be a growth year for the company post-remediation and new approvals from the Gagillapur facility.
We revise our FY26E/FY27E EPS estimates by 0.3%/0.2%.
We roll over to FY28E and maintain ‘Accumulate' rating with target price of Rs 617 at 18x FY28E P/E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
